medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

1

Classification:

2

Biological Sciences, Biophysics and Computational Biology

3

Modelling SARS-CoV-2 Dynamics: Implications

4

for Therapy

5

Kwang Su Kima, Keisuke Ejimab, Yusuke Itoa, Shoya Iwanamia, Hirofumi Ohashic,

6

Yoshiki Koizumid, Yusuke Asaid, Shinji Nakaokae,f, Koichi Watashic,g,h,i,j, Robin N.

7

Thompsonk,l,1, and Shingo Iwamia,h,i,m,1

8
9

aDepartment

of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan

10

8190395. bDepartment of Epidemiology and Biostatistics, Indiana University School

11

of Public Health-Bloomington, IN, USA 47405. cDepartment of Virology II, National

12

Institute of Infectious Diseases, Tokyo, Japan 1628640. dNational Center for Global

13

Health and Medicine, Tokyo, Japan 1628655. eFaculty of Advanced Life Science,

14

Hokkaido University, Sapporo, Japan 060-0808. fPRESTO, JST, Saitama, Japan

15

3320012. gDepartment of Applied Biological Science, Tokyo University of Science,

16

Noda, Japan 2788510.

17

Saitama, Japan 3320012. jInstitute for Frontier Life and Medical Sciences, Kyoto

18

University, Kyoto, Japan 6068507. kChrist Church, University of Oxford, Oxford OX1

19

1DP, UK. lMathematical Institute, University of Oxford, Oxford OX2 6GG, UK,

20

Fukuoka, UK. mScience Groove Inc., Fukuoka, Japan 8100041.

hMIRAI,

JST, Saitama, Japan 3320012. iCREST, JST,

21
22
23

1To

whom correspondence may be addressed.

Email: robin.thompson@chch.ox.ac.uk (R.N.T.) and siwami@kyushu-u.org (S.I.).
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

24

Abstract (230/250)

25

The scientific community is focussed on developing antiviral therapies to

26

mitigate the impacts of the ongoing novel coronavirus disease (COVID-19) outbreak.

27

This will be facilitated by improved understanding of viral dynamics within infected

28

hosts. Here, using a mathematical model in combination with published viral load

29

data collected from the same specimen (throat / nasal swabs or nasopharyngeal /

30

sputum / tracheal aspirate), we compare within-host dynamics for patients infected in

31

the current outbreak with analogous dynamics for MERS-CoV and SARS-CoV

32

infections. Our quantitative analyses revealed that SARS-CoV-2 infection dynamics

33

are more severe than those for mild cases of MERS-CoV, but are similar to severe

34

cases, and that the viral dynamics of SARS-CoV infection are similar to those of

35

MERS-CoV in mild cases but not in severe case. Consequently, SARS-CoV-2

36

generates infection dynamics that are more severe than SARS-CoV. Furthermore,

37

we used our viral dynamics model to predict the effectiveness of unlicensed drugs

38

that have different methods of action. The effectiveness was measured by AUC of

39

viral load. Our results indicated that therapies that block de novo infections or virus

40

production are most likely to be effective if initiated before the peak viral load (which

41

occurs around three days after symptom onset on average), but therapies that

42

promote cytotoxicity are likely to have only limited effects. Our unique mathematical

43

approach provides insights into the pathogenesis of SARS-CoV-2 in humans, which

44

are useful for development of antiviral therapies.

45

Keywords:

46

SARS-CoV-2, MERS-CoV, SARS-CoV, mathematical model, antiviral therapy

2

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

47

Significance Statement (80/120)

48

Antiviral agents with different mechanisms of action have different curative effects

49

depending on precisely when therapy is initiated. Based on a model of viral

50

dynamics, parameterised using viral load data from SARS-CoV-2 infected patients

51

reported by Zou et al. (1), computer simulations were performed. We propose that

52

effective treatment of SARS-CoV-2 infection requires an appropriate choice of class-

53

specific drugs and initiation timing as reported for treatment of other viral infections

54

(2); otherwise, antivirals do not have a significant effect on the within-host viral

55

dynamics of SARS-CoV-2 and are wasted.

3

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

56

\body

57

Text

58

The ongoing coronavirus disease 2019 (COVID-19) outbreak was first

59

reported in Wuhan, China in late December 2019 (3, 4). Since then, the causative

60

agent (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) has been

61

transmitted elsewhere in China and to 80 other countries and territories around the

62

world. The number of confirmed cases currently stands at 139,061 (as of 13 March

63

2020). The possibility of presymptomatic or asymptomatic cases (5), combined with

64

underreporting of symptomatic infections, suggests that the true number of cases is

65

likely to be even higher than this.

66

Antiviral drugs (for treatment and to avoid onwards transmission) and a

67

vaccine (for prevention) are currently under development to counter this outbreak. To

68

aid the development process, characterisation of the viral dynamics of SARS-CoV-2

69

both in vivo and in vitro is crucial. The virus has been isolated, genome sequencing

70

has been completed and the resulting data were made publicly available early in the

71

outbreak (6, 7). Furthermore, the viral load in upper respiratory specimens (throat

72

and nasal swabs) of infected patients over 20 days after symptom onset has been

73

reported (2). However, the viral dynamics of SARS-CoV-2 infections have not been

74

studied quantitatively, and the data have not been compared with analogous

75

datasets for other coronaviruses. Such quantitative analyses are informative for the

76

development of antiviral agents, addressing questions such as the optimal viral-host

77

processes for antiviral drugs or vaccines to target.

4

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

78

Results and Discussion

79

Characterising SARS-CoV-2 and MERS-CoV infections by analysing viral load

80

measurements collected from throat swabs

81

We analysed data describing SARS-CoV-2 viral loads reported by Zou et al.

82

(1) and MERS-CoV viral loads reported by Oh et al. (8) using a simple mathematical

83

model (see Methods). To consider inter-individual variations in viral loads, a

84

nonlinear mixed-effect modelling approach was employed to estimate parameters

85

(see Methods). The estimated parameters and initial values are listed in Table 1,

86

and the typical behaviour of the model using these best-fit parameter estimates is

87

shown together with the data in Fig. 1A for SARS-CoV-2 (pink) and MERS-CoV

88

(black and grey for severe and mild case, respectively). In addition, to parameterise

89

and compare these coronaviruses infections, we calculated the following important

90

quantities (Fig. 2) using estimated parameter values; the mean length of virus

91

production of an infected cell (ğ¿ğ¿ = 1/ğ›¿ğ›¿), the within-host basic reproduction number

92
93
94
95
96

(ğ‘…ğ‘…0 = ğ›¾ğ›¾/ğ›¿ğ›¿) which is the average number of newly infected cells produced by any

single infected cell (9), and the critical inhibition rate (ğ¶ğ¶ âˆ— = 1 âˆ’ 1/ğ‘…ğ‘…0 ) induced by

antivirals to prevent primary virus infection (10, 11). We showed that ğ¿ğ¿ is not

significantly different for SARS-CoV-2 and MERS-CoV. However, interestingly, we
found that ğ‘…ğ‘…0 and ğ¶ğ¶ âˆ— for SARS-CoV-2 are significantly different from analogous

98

values for mild cases of MERS-CoV (ğ‘ğ‘ = 8.9 Ã— 10âˆ’4 and 2.0 Ã— 10âˆ’6 by the bootstrap

99

t-test, respectively), but not for severe MERS-CoV (ğ‘ğ‘ = 0.41 and 0.41) (see Fig. 2),
although we were unable to separate mild and severe cases of SARS-CoV-2 due to

100

limited clinical information for the cases. This demonstrates that SARS-CoV-2

101

causes infection more effectively than in mild cases of MERS-CoV, but a general

102

SARS-CoV-2 infection follows infection dynamics that are similar to severe cases

97

5

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

103

due to MERS-CoV. In addition, as a median estimate, 65% inhibition of the initial

104

virus expansion is required to prevent the establishment of SARS-CoV-2 infection

105

(we provide a detailed analysis later). We also calculated the duration of infection in

106

which the viral load is above the detection limit (ğ‘‡ğ‘‡ğ‘‰ğ‘‰ğ‘‰ğ‘‰ ) in Table 1, showing that SARS-

107

CoV-2 is maintained in hosts for more than a week based on the median estimate.

108
109

Characterising SARS-CoV and MERS-CoV infections by analysing viral load

110

measurements collected from nasopharyngeal/sputum/tracheal aspirate

111

To extend our analysis to include SARS-CoV, we analysed SARS-CoV viral

112

loads in nasopharyngeal aspirate reported by Peiris et al. (12) and MERS-CoV viral

113

loads reported by Oh et al. (8) in sputum or tracheal aspirate. The estimated

114

parameters, viral load at symptom onset, and the indices derived from the estimated

115

parameters are listed in Table 1 and Fig. 2, and the typical behaviour of the model is

116

shown together with the data in Fig. 1B for SARS-CoV (blue) and MERS-CoV (black

117

or grey). The estimated values of ğ¿ğ¿ for SARS-CoV and MERS-CoV are not

118
119

significantly different. Surprisingly, the estimated values of ğ‘…ğ‘…0 and ğ¶ğ¶ âˆ— for SARS-CoV

120

are significantly different from those for severe cases of MERS-CoV (ğ‘ğ‘ = 0.03 and

121

0.02 from bootstrap t-test), but not for mild MERS-CoV cases (ğ‘ğ‘ = 0.52 and 0.47

from bootstrap t-test) (Fig. 2). This demonstrates that in vivo viral dynamics of

122

SARS-CoV infection are similar to those for MERS-CoV in mild cases but not in

123

severe cases. Collectively, the findings from the viral load data analyses for the two

124

different specimens (throat/nasal swabs and nasopharyngeal/sputum/tracheal

125

aspirate) implied that SARS-CoV-2 also causes infection more effectively than

126

SARS-CoV.

127
6

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

128

Evaluation of anti-SARS-CoV-2 therapies

129

Our quantitative analyses provide insights into optimal usage of anti-SARS-

130

CoV-2 therapies under development. In particular, it remains poorly understood how

131

a delay of treatment initiation after primary infection, or how incomplete blocking of

132

virus infection/replication, impacts the viral load dynamics. Based on our

133

mathematical model and estimated parameter values (Table 1), we conducted in

134

silico experiments for possible anti-SARS-CoV-2 therapies to investigate the

135

expected outcome under hypothetical drug therapies (or vaccine use) possessing

136

different antiviral mechanisms (Fig. 3).

137
138

(i) Blocking de novo infection

139

One of the major mechanisms of action for antivirals is blocking de novo

140

infections. This can be induced by drugs including human neutralising antibodies,

141

viral entry-inhibitors and/or antibodies raised by vaccination (13, 14). For example, a

142

SARS-CoV-specific human monoclonal antibody has been reported to cross react

143

with SARS-CoV-2 (14). We conducted in silico experiments with varying drug

144

efficacy (considering inhibition rates from 10% to 100%, i.e. 0.1 â‰¤ ğœ€ğœ€ â‰¤ 1) and with the

145

timing of initiation of therapy from 0 days (i.e., post-exposure prophylactic use of

146
147

antivirals) until 5 days after symptom onset (i.e., 0 â‰¤ ğ‘¡ğ‘¡ âˆ— â‰¤ 5) (see Methods). Our

148

even a relatively weak drug (inhibition rates as low as 50%) might effectively reduce

149

the area under the curve of viral load (AUC) and prevent significant reductions in the

150

numbers of target cells because of cytopathic effects due to cell invasion. A therapy

151

of this type initiated four days after symptom onset, on the other hand, is not

152

predicted to induce a clear antiviral effect (Fig. 3AD). This suggests that blocking de

results show that early initiation of therapy (especially within two to three days) with

7

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

153

novo infections is not likely to be effective unless the intervention is initiated before

154

the peak viral load. Hence, appropriate initiation timing (i.e., before or very soon after

155

symptom onset) is an important factor for suppressing viral load in addition to the

156

therapy having the potential for antiviral effects.

157
158

(ii) Blocking virus production

159

The majority of antiviral drugs inhibit intracellular virus replication. Although

160

their antiviral efficacies need to be confirmed, lopinavir/ritonavir (HIV protease

161

inhibitors), remdesivir (anti-Ebola virus disease candidate) and other nucleoside

162

analogues, and interferon have the potential to suppress SARS-CoV-2 by blocking

163

virus production(15, 16). Interestingly, our results suggest that, even for relatively

164

small inhibition rates of around 30%, the AUC of viral load is partially reduced if

165

therapy is initiated early (within three days after symptom onset) (Fig. 3BE).

166

However, if treatment is applied after the peak viral load, even drugs with 100%

167

inhibition rate are not able to reduce viral loads, which is similar to the predicted

168

outcomes of de novo blocking therapy.

169
170

(iii) Promoting cytotoxicity

171

Another possible antiviral mechanism is cytotoxic effects by adaptive

172

immunity including those mediated by cytotoxic T lymphocytes. Here, we assume

173

that promoting cytotoxicity increases the virus death rate by at most two times (i.e.,

174
175

0.1 â‰¤ ğœƒğœƒ â‰¤ 1), that is, achieves up to 50% reduction of the mean length of virus

176

virus production), the induction of cytotoxicity had relatively mild effects on the AUC

177

reduction if initiated before peak viral load. However, cytotoxicity induction initiated

production. Compared with the other two therapies (blocking de novo infection and

8

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

178

after peak viral load could effectively reduce the viral load AUC (Fig. 3CF). This

179

implies that there is an optimal time to apply this therapy, and that significant antiviral

180

effects are expected unless the promoting rate is too low or therapy is initiated either

181

too early or too late. However, large reductions of target cells due to ongoing de

182

novo infection cannot be avoided even with very early initiation (i.e., immediately

183

after symptom onset) of the therapy.

9

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

184

Conclusions

185

There are a number of potential transmission routes of SARS-CoV-2,

186

including direct person-to-person transmission due to viral particle inhalation and

187

contact transmission due to contact with nasal/oral/eye mucuous membranes. The

188

risk of transmission depends on the viral load of the potential infector. Consequently,

189

treatments reducing the viral load are important for the prevention of secondary

190

transmission and aid population-scale outbreak control. We characterised viral

191

infection dynamics using a mathematical model, and assessed potential strategies to

192

reduce viral loads. Our analyses showed that both blocking de novo infection and

193

virus production effectively reduces AUC of SARS-CoV-2 load; for example, if the

194

therapy can reduce more than 90% of de novo infections and is initiated 3 days after

195

symptoms onset, the viral load AUC is expected to be reduced by 81.4% (Fig. 3DE).

196

However, if therapy is initiated after peak viral load (more than 2-3 days following

197

symptom onset), the effect on viral load AUC is limited. Compared with either

198

blocking de novo infection or virus production, promoting cytotoxicity showed

199

relatively mild effects on AUC reduction, however initiation of that therapy after the

200

peak viral load has the potential to still reduce viral load AUC (Fig. 3F).

201

The effectiveness of the hypothetical drugs can be evaluated in detail using a

202

cell culture system supporting SARS-CoV-2 infection (13). Wang et al. proposed

203

different classes of drugs for treating SARS-CoV-2 infections: chloroquine inhibited

204

viral entry and remdesivir suppressed the virus post-entry, likely by suppressing viral

205

replication (13). Although animal models for testing treatments have not been

206

reported for SARS-CoV-2, a number of animal models exist for SARS-CoV including

207

mice, hamsters, ferrets, and macaques (17). Animals could be used to verify the

208

conclusions from our models, by monitoring the viral loads in animals treated with
10

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

209

different types of drugs at different doses and different initiation timings. Such viral

210

load data would allow further investigation of the effectiveness of drugs with different

211

action mechanisms, which would be informative for development of appropriate

212

treatment strategies (i.e., the optimal dose/timing of antivirals) for SARS-CoV-2

213

infections.

214

In conclusion, effective treatment of SARS-CoV-2 infections requires an

215

appropriate choice of class-specific drugs; otherwise, the antivirals do not alter the

216

viral load significantly and are wasted. Identification of SARS-CoV-2-specific virus

217

characteristics is needed to design optimal treatments and to ensure that limited

218

resources are deployed effectively. Additionally, effective combinations of anti-

219

SARS-CoV-2 drugs and vaccines will maximise the impacts of control, reduce the

220

required drug dose and potentially limit side effects, all of which are highly desirable.

221

Our theoretical approach could complement ongoing experimental investigations into

222

SARS-CoV-2 infection in BSL-3 laboratories and help establish a basis for COVID-

223

19 treatment. To our knowledge, previous studies have neither characterised SARS-

224

CoV-2 dynamics in humans using viral dynamics models, nor compared the resulting

225

dynamics against those of other coronaviruses (i.e., SARS-CoV and MERS-CoV).

226

Our mathematical modelling approach has led to an improved understanding of the

227

characteristics of SARS-CoV-2 in vivo, and can be used to test possible treatments

228

for COVID-19 further going forwards.

11

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

229

Methods

230

Study data

231

The data examined in our manuscript came from studies of SARS-CoV-2,

232

MERS-CoV and SARS-CoV by Zou et al. (1), Oh et al. (8) and Peiris et al. (12),

233

respectively. To extract the data from images in those publications, we used the

234

program datathief III (version 1.5, Bas Tummers, www.datathief.org). We excluded

235

patients for whom data were measured on only one day, and assumed that viral load

236

values under the detection limit were set as the detection limit for the purposes of

237

fitting the model. We converted cycle threshold (Ct) values reported in Zou et al. (1),

238

Oh et al. (8) and Peiris et al. (12) to viral RNA copies number values, where these

239

quantities are inversely proportional to each other (18).

240
241

Mathematical model

242

To parameterise coronavirus infection dynamics from patient viral load data,

243

we derived a simplified mathematical model from the following virus dynamics

244

model:

245

246

247
248
249

ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘¡ğ‘¡)
= âˆ’ğ›½ğ›½ğ›½ğ›½(ğ‘¡ğ‘¡)ğ‘‰ğ‘‰(ğ‘¡ğ‘¡),
ğ‘‘ğ‘‘ğ‘‘ğ‘‘

(1)

ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘¡ğ‘¡)
= ğ‘ğ‘ğ‘ğ‘(ğ‘¡ğ‘¡) âˆ’ ğ‘ğ‘ğ‘ğ‘(ğ‘¡ğ‘¡),
ğ‘‘ğ‘‘ğ‘‘ğ‘‘

(3)

ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘¡ğ‘¡)
= ğ›½ğ›½ğ›½ğ›½(ğ‘¡ğ‘¡)ğ‘‰ğ‘‰(ğ‘¡ğ‘¡) âˆ’ ğ›¿ğ›¿ğ›¿ğ›¿(ğ‘¡ğ‘¡),
ğ‘‘ğ‘‘ğ‘‘ğ‘‘

(2)

where the variables ğ‘‡ğ‘‡(ğ‘¡ğ‘¡), ğ¼ğ¼(ğ‘¡ğ‘¡) and ğ‘‰ğ‘‰(ğ‘¡ğ‘¡) are the numbers of uninfected target cells,

250

infected target cells, and the amount of virus at time ğ‘¡ğ‘¡, respectively. The parameters

251

cells, the viral production rate, and the clearance rate of the virus, respectively. Since

ğ›½ğ›½, ğ›¿ğ›¿, ğ‘ğ‘, and ğ‘ğ‘ represent the rate constant for virus infection, the death rate of infected
12

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

252

the clearance rate of virus is typically much larger than the death rate of the infected

253

cells in vivo (10, 19, 20), we made a quasi-steady state (QSS) assumption,

254

ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘¡ğ‘¡)â„ğ‘‘ğ‘‘ğ‘‘ğ‘‘ = 0 , and replaced Eq.(3) with ğ‘‰ğ‘‰(ğ‘¡ğ‘¡) = ğ‘ğ‘ğ‘ğ‘(ğ‘¡ğ‘¡)â„ğ‘ğ‘ . Because data on the

255
256
257
258

numbers of coronavirus RNA copies, ğ‘‰ğ‘‰(ğ‘¡ğ‘¡), rather than the number of infected cells,
ğ¼ğ¼(ğ‘¡ğ‘¡), were available, then ğ¼ğ¼(ğ‘¡ğ‘¡) = ğ‘ğ‘ğ‘ğ‘(ğ‘¡ğ‘¡)â„ğ‘ğ‘ was substituted into Eq.(2) to obtain
ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘¡ğ‘¡) ğ‘ğ‘ğ‘ğ‘
=
ğ‘‡ğ‘‡(ğ‘¡ğ‘¡)ğ‘‰ğ‘‰(ğ‘¡ğ‘¡) âˆ’ ğ›¿ğ›¿ğ›¿ğ›¿(ğ‘¡ğ‘¡).
ğ‘‘ğ‘‘ğ‘‘ğ‘‘
ğ‘ğ‘

(4)

259

Furthermore, we defined the ratio of the number of uninfected target cells at time ğ‘¡ğ‘¡ to

260

the initial number of uninfected target cells ğ‘‡ğ‘‡(0) , that is, ğ‘“ğ‘“(ğ‘¡ğ‘¡) = ğ‘‡ğ‘‡(ğ‘¡ğ‘¡)â„ğ‘‡ğ‘‡(0) .

Accordingly, we obtained the following simplified mathematical model, which we

261

employed to analyse the data in this study:

262

263
264
265

ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘¡ğ‘¡)
= âˆ’ğ›½ğ›½ğ›½ğ›½(ğ‘¡ğ‘¡)ğ‘‰ğ‘‰(ğ‘¡ğ‘¡),
ğ‘‘ğ‘‘ğ‘‘ğ‘‘

ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘¡ğ‘¡)
= ğ›¾ğ›¾ğ›¾ğ›¾(ğ‘¡ğ‘¡)ğ‘‰ğ‘‰(ğ‘¡ğ‘¡) âˆ’ ğ›¿ğ›¿ğ›¿ğ›¿(ğ‘¡ğ‘¡),
ğ‘‘ğ‘‘ğ‘‘ğ‘‘

(5)
(6)

where ğ›¾ğ›¾ = ğ‘ğ‘ğ‘ğ‘ğ‘ğ‘(0)/ğ‘ğ‘ is defined as the maximum viral replication rate for coronavirus

266

infections. Note that the ratio ğ‘“ğ‘“(ğ‘¡ğ‘¡) is always less than or equal to 1.

267

for SARS-CoV-2 and MERS-CoV and in nasopharyngeal/sputum/tracheal aspirate

268

for SARS-CoV and MERS-CoV. In the case of acute coronavirus infection, the loss

269

of target cells by physiological turnover could be ignored, considering the long life-

270

span of the target cells. Patient viral load data for SARS-CoV-2/SARS-CoV/MERS-

271

CoV were fitted using a nonlinear mixed-effect modelling approach (described

272

below), which uses the whole sample to estimate population parameters but also

273

account for inter-individual variation.

In our analyses, the variable ğ‘‰ğ‘‰(ğ‘¡ğ‘¡) corresponds to the viral load in throat swabs

274
13

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

275

In silico experiments for possible anti-SARS-CoV-2 therapies

276

By utilising our novel mathematical model and the estimated parameter

277

values, we investigated the antiviral effects of unlicensed but developing (promising)

278

drugs with the following different mechanisms of action, depending on inhibition rates

279

and timings of therapy initiation: (i) blocking de novo infection (e.g. via human

280

neutralising antibodies, viral entry-inhibitors and antibody levels raised by

281

vaccination (13, 14)); (ii) blocking virus production (such as lopinavir/ritonavir (HIV

282

protease inhibitors), remdesivir (an anti-Ebola virus candidate) and other nucleoside

283

analogues, and interferon (15, 16)); and (iii) promoting cytotoxicity (by adaptive

284

immunity such as cytotoxic T lymphocytes). To simulate possible variations in the

285

viral load and in the target cell numbers under these different types of anti-SARS-

286

CoV-2 therapy, the median parameter sets were used to predict the expected

287

outcome of each therapy. In other words, even though no drug administration trials

288

have been conducted yet, we were able to infer the efficacy of each drug treatment

289

based on our in silico experiments. We implemented the different mechanisms of

290

action in the model as follows:

291

(i) Blocking de novo infection. The antiviral effect of blocking de novo infection

292

therapy (0 < ğœ€ğœ€ â‰¤ 1. ğœ€ğœ€ = 1 implies de novo infection is 100% inhibited) initiated at ğ‘¡ğ‘¡ âˆ—

293
294

295
296
297
298

days after symptom onset was modelled by assuming:
ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘¡ğ‘¡)
= âˆ’ï¿½1 âˆ’ ğœ€ğœ€ Ã— ğ»ğ»(ğ‘¡ğ‘¡)ï¿½ğ›½ğ›½ğ›½ğ›½(ğ‘¡ğ‘¡)ğ‘‰ğ‘‰(ğ‘¡ğ‘¡),
ğ‘‘ğ‘‘ğ‘‘ğ‘‘

ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘¡ğ‘¡)
= ï¿½1 âˆ’ ğœ€ğœ€ Ã— ğ»ğ»(ğ‘¡ğ‘¡)ï¿½ğ›¾ğ›¾ğ›¾ğ›¾(ğ‘¡ğ‘¡)ğ‘‰ğ‘‰(ğ‘¡ğ‘¡) âˆ’ ğ›¿ğ›¿ğ›¿ğ›¿(ğ‘¡ğ‘¡),
ğ‘‘ğ‘‘ğ‘‘ğ‘‘

(7)
(8)

where ğ»ğ»(ğ‘¡ğ‘¡) is a Heaviside step function defined as ğ»ğ»(ğ‘¡ğ‘¡) = 0 if ğ‘¡ğ‘¡ < ğ‘¡ğ‘¡ âˆ— : otherwise

ğ»ğ»(ğ‘¡ğ‘¡) = 1. We evaluated the expected antiviral effect of the therapy under different
inhibition rates (ğœ€ğœ€) and initiation timings (ğ‘¡ğ‘¡ âˆ— ) using our estimated parameter values.
14

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

299

The mean reduction of cumulative virus production, i.e., the area under the curve of

300
301

viral load (AUC: âˆ«0 ğ‘‰ğ‘‰(ğ‘ ğ‘ )ğ‘‘ğ‘‘ğ‘‘ğ‘‘: because the observed durations COVID-19 infection are

302

used the maximum length of observations 28 days as the upper bound for

303

integration), induced by blocking de novo infection for SARS-CoV-2 was calculated.

304
305

Note that the expected values at day 0 after symptom onset (ğ‘¡ğ‘¡ âˆ— = 0) corresponds to

306

(ii) Blocking virus production. Alternatively, we assumed an inhibition rate of

307

virus production of 0 < ğœ‚ğœ‚ â‰¤ 1. The antiviral effect by blocking virus production (0 <

308
309
310

28

longer than previous coronavirus infection (i.e., SARS-CoV and MERS-CoV), we

the antiviral effect of therapy initiated immediately after symptom onset.

ğœ‚ğœ‚ â‰¤ 1. ğœ‚ğœ‚ = 1 indicates that the virus reproduction from the infected cells are perfectly
inhibited) is modelled as follows:

ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘¡ğ‘¡)
= ï¿½1 âˆ’ ğœ‚ğœ‚ Ã— ğ»ğ»(ğ‘¡ğ‘¡)ï¿½ğ›¾ğ›¾ğ›¾ğ›¾(ğ‘¡ğ‘¡)ğ‘‰ğ‘‰(ğ‘¡ğ‘¡) âˆ’ ğ›¿ğ›¿ğ›¿ğ›¿(ğ‘¡ğ‘¡).
ğ‘‘ğ‘‘ğ‘‘ğ‘‘

(9)

311

Note that the difference between blocking de novo infection and virus production is

312

that the former reduces ğ›½ğ›½, whereas the latter reduces ğ‘ğ‘ in the full model (1)-(3).

313
314
315
316
317
318

(iii) Promoting cytotoxicity. The antiviral effect of promoting cytotoxicity

therapy (0 < ğœƒğœƒ â‰¤ 1. ğœƒğœƒ = 1 indicates that the mean duration of virus production is
doubled) was modelled as follows:

ğ‘‘ğ‘‘ğ‘‘ğ‘‘(ğ‘¡ğ‘¡)
= ğ›¾ğ›¾ğ›¾ğ›¾(ğ‘¡ğ‘¡)ğ‘‰ğ‘‰(ğ‘¡ğ‘¡) âˆ’ ï¿½1 + ğœƒğœƒ Ã— ğ»ğ»(ğ‘¡ğ‘¡)ï¿½ğ›¿ğ›¿ğ›¿ğ›¿(ğ‘¡ğ‘¡).
ğ‘‘ğ‘‘ğ‘‘ğ‘‘

(10)

The nonlinear mixed effect model

319

MONOLIX 2019R2 (www.lixoft.com), a program that implements a maximum

320

likelihood estimation procedure for parameters in a nonlinear mixed-effects model,

321

was employed to fit to the viral load data. Nonlinear mixed-effects modelling

322

approaches allow a fixed effect as well as a random effect describing the inter15

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

323

patient variability. Including a random effect amounts to a partial pooling of the data

324

between individuals to improve estimates of the parameters applicable across the

325

population of patients. By using this approach, the differences between viral

326

dynamics in different patients were not estimated explicitly, nor did we fully pool the

327

data which would bias estimates towards highly sampled patients. In this method of

328

estimation, each parameter estimate ğœ—ğœ—ğ‘–ğ‘– (= ğœ—ğœ— Ã— ğ‘’ğ‘’ ğœ‹ğœ‹ğ‘–ğ‘– ) depends on the individual where

329
330

ğœ—ğœ— is fixed effect, and ğœ‹ğœ‹ğ‘–ğ‘– is random effect with an assumed Gaussian distribution with

331

mean 0 and standard deviation Î©. Population parameters and individual parameters

332

algorithm

333

parameters and initial values for patients are summarized in Table S1. Using

334

estimated individual parameters and a Markov chain Monte Carlo algorithm, the

335

conditional distribution is obtained which can represent the uncertainty in individual

336

parameter values. We obtained 100 sets of estimated parameters for each individual

337

patient by fitting the simplified mathematical model (Eqs. (5-6)) to the data. The

338

estimation was performed for viral loads in throat swab from SARS-CoV-2, mild

339

MERS-CoV, and severe MERS-CoV separately, and the distributions of the

340

parameters were compared and tested using the bootstrap t-test. Due to the small

341

sample size for viral loads in sputum/tracheal aspirate for MERS-CoV, we assumed

342

the fixed effect was the same for mild and severe MERS-CoV cases. Otherwise, the

343

process was exactly the same as that described for the throat swab data.

were estimated using the stochastic approximation expectation-maximisation
and

empirical

Bayesâ€™

method,

respectively.

Individual

estimated

344
345
346
347

The computation of ğ‘³ğ‘³, ğ‘¹ğ‘¹ğŸğŸ , ğ‘ªğ‘ªâˆ— and ğ‘»ğ‘»ğ‘½ğ‘½ğ‘½ğ‘½

Based on the estimated parameter distributions, we calculated several

quantities: the duration of virus production (ğ¿ğ¿), the basic reproduction number (ğ‘…ğ‘…0 ),
16

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

348
349

and the critical inhibition rate (ğ¶ğ¶ âˆ— ). We also calculated the period during which the
viral load was above the detection limit (ğ‘‡ğ‘‡ğ‘‰ğ‘‰ğ‘‰ğ‘‰ ) from the in silico simulations with

350

individual estimated parameters and an initial viral load equal the detection limit (i.e.

351

numerical experiments began at the point at which the virus became detectable).

352

The distributional estimates of ğ‘…ğ‘…0 , ğ¿ğ¿ , ğ¶ğ¶ âˆ— and ğ‘‡ğ‘‡ğ‘‰ğ‘‰ğ‘‰ğ‘‰ were calculated separately for

353

SARS-CoV-2 and SARS-CoV, as well as for severe and mild cases of MERS-CoV.

17

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

354

Acknowledgments

355

This study was supported in part by Basic Science Research Program

356

through the National Research Foundation of Korea funded by the Ministry of

357

Education 2019R1A6A3A12031316 (to K.S.K.); Grants-in-Aid for JSPS Scientific

358

Research (KAKENHI) Scientific Research B 17H04085 (to K.W.), 18KT0018 (to S.I.),

359

18H01139 (to S.I.), 16H04845 (to S.I.), Scientific Research S 15H05707 (to S.N.),

360

Scientific Research in Innovative Areas 19H04839 (to S.I.), 18H05103 (to S.I.);

361

AMED CREST 19gm1310002 (to S.I.); AMED J-PRIDE 19fm0208019j0003 (to K.W.),

362

19fm0208006s0103 (to S.I.), 19fm0208014h0003 (to S.I.), 19fm0208019h0103 (to

363

S.I.); AMED Research Program on HIV/AIDS 19fk0410023s0101 (to S.I.); Research

364

Program on Emerging and Re-emerging Infectious Diseases 19fk0108050h0003 (to

365

S.I.); Program for Basic and Clinical Research on Hepatitis 19fk0210036j0002 (to

366

K.W.), 19fk0210036h0502 (to S.I.); Program on the Innovative Development and the

367

Application

368

19fk0310101j1003 (to K.W.) , 19fk0310103j0203 (to K.W.), 19fk0310114h0103 (to

369

S.I.); JST PRESTO (to S.N.); JST MIRAI (to K.W. and S.I.); JST CREST (to K.W.

370

and S.I.); The Yasuda Medical Foundation (to K.W.); Smoking Research Foundation

371

(to K.W.); Takeda Science Foundation (to K.W.); Mochida Memorial Foundation for

372

Medical and Pharmaceutical Research (to K.W.); Mitsui Life Social Welfare

373

Foundation (to S.I. and K.W.); Shin-Nihon of Advanced Medical Research (to S.I.);

374

Suzuken Memorial Foundation (to S.I.); Life Science Foundation of Japan (to S.I.);

375

SECOM Science and Technology Foundation (to S.I.); The Japan Prize Foundation

376

(to S.I.); Toyota Physical and Chemical Research Institute (to S.I.); Fukuoka

377

Financial Group, Inc. (to S.I.); Kyusyu Industrial Advancement Center Gapfund

of

New

Drugs

for

Hepatitis

18

B

19fk0310114j0003

(to

K.W.),

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

378

Program (to S.I.); Foundation for the Fusion Of Science and Technology (to S.I.); a

379

Junior Research Fellowship from Christ Church, Oxford (to R.N.T.)

380
381
382

Competing interests
The authors declare that they have no competing interests.

383
384

Authorsâ€™ contributions

385

Conceived and designed the study: KE KW RNT SI. Analysed the data: KSK

386

KE YI SI HO YK SN SI. Wrote the paper: KSK KE KW RNT SI. All authors read and

387

approved the final manuscript.

19

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

388

References

389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436

1.
2.

3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.

Zou L, et al. (2020) SARS-CoV-2 Viral Load in Upper Respiratory Specimens of
Infected Patients. N Engl J Med.
Fry AM, et al. (2014) Efficacy of oseltamivir treatment started within 5 days of
symptom onset to reduce influenza illness duration and virus shedding in an urban
setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis
14(2):109-118.
Li Q, et al. (2020) Early Transmission Dynamics in Wuhan, China, of Novel
Coronavirus-Infected Pneumonia. N Engl J Med.
Thompson RN (2020) Novel Coronavirus Outbreak in Wuhan, China, 2020: Intense
Surveillance Is Vital for Preventing Sustained Transmission in New Locations. J Clin
Med 9(2).
Chan JF, et al. (2020) A familial cluster of pneumonia associated with the 2019 novel
coronavirus indicating person-to-person transmission: a study of a family cluster.
Lancet 395(10223):514-523.
Zhu N, et al. (2020) A Novel Coronavirus from Patients with Pneumonia in China,
2019. N Engl J Med 382(8):727-733.
Lu R, et al. (2020) Genomic characterisation and epidemiology of 2019 novel
coronavirus: implications for virus origins and receptor binding. Lancet
395(10224):565-574.
Oh MD, et al. (2016) Viral Load Kinetics of MERS Coronavirus Infection. N Engl J
Med 375(13):1303-1305.
Perelson AS (2002) Modelling viral and immune system dynamics. Nat Rev Immunol
2(1):28-36.
Martyushev A, Nakaoka S, Sato K, Noda T, & Iwami S (2016) Modelling Ebola virus
dynamics: Implications for therapy. Antiviral Res 135:62-73.
Iwami S, et al. (2012) Identifying viral parameters from in vitro cell cultures. Front
Microbiol 3:319.
Peiris JS, et al. (2003) Clinical progression and viral load in a community outbreak of
coronavirus-associated SARS pneumonia: a prospective study. Lancet
361(9371):1767-1772.
Wang M, et al. (2020) Remdesivir and chloroquine effectively inhibit the recently
emerged novel coronavirus (2019-nCoV) in vitro. Cell Res.
Tian X, et al. (2020) Potent binding of 2019 novel coronavirus spike protein by a
SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect
9(1):382-385.
Yao TT, Qian JD, Zhu WY, Wang Y, & Wang GQ (2020) A Systematic Review of
Lopinavir Therapy for SARS Coronavirus and MERS Coronavirus-A Possible
Reference for Coronavirus Disease-19 Treatment Option. J Med Virol.
Lu H (2020) Drug treatment options for the 2019-new coronavirus (2019-nCoV).
Biosci Trends.
Peiris JS, Yuen KY, Osterhaus AD, & Stohr K (2003) The severe acute respiratory
syndrome. N Engl J Med 349(25):2431-2441.
Poon LL, et al. (2004) Detection of SARS coronavirus in patients with severe acute
respiratory syndrome by conventional and real-time quantitative reverse transcriptionPCR assays. Clin Chem 50(1):67-72.
Ikeda H, et al. (2016) Quantifying the effect of Vpu on the promotion of HIV-1
replication in the humanized mouse model. Retrovirology 13:23.
Nowak MA & May RM (2000) Virus dynamics. (Oxford University Press Oxford).
20

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

437

Figure legends

438

Fig. 1. Mathematical model outputs for individual patients based on fits to viral load

439

data for SARS-CoV-2, MERS-CoV and SARS-CoV. Viral loads were measured using

440

throat swabs for SARS-CoV-2 and MERS-CoV (A) and nasoparyngeal/sputum

441

swabs or tracheal aspirate for SARS-CoV and MERS-CoV (B) infected patients.

442

Severe and mild cases of MERS-CoV are shown in black and gray, respectively.

443

Note that the detection limits of measurements of SARS-CoV-2, MERS-CoV and

444

SARS-CoV viral loads are 14.6, 1000 and 1000 copies/ml, respectively.

445
446

Fig. 2. Characterisation and comparison of SARS-CoV-2, MERS-CoV and SARS-

447

CoV infection dynamics in vivo. Distribution of estimates for (A) the mean duration of

448

virus production of an infected cell, ğ¿ğ¿ = 1/ğ›¿ğ›¿, (B) the within-host basic reproduction

450

number, ğ‘…ğ‘…0 = ğ›¾ğ›¾/ğ›¿ğ›¿, and (C) the critical inhibition rate, ğ¶ğ¶ âˆ— = 1 âˆ’ 1/ğ‘…ğ‘…0 . Estimates of ğ‘…ğ‘…0

451

and ğ¶ğ¶ âˆ— for SARS-CoV-2 are significantly different compared to analogous estimates
for mild cases of MERS-CoV, but not compared to estimates for severe MERS-CoV.

452

On the other hand, estimates for SARS-CoV are significantly different from those for

453

severe cases of MERS-CoV but not for mild cases of MERS-CoV.

449

454
455

Fig. 3. In silico experiments to predict the outcomes of possible anti-SARS-CoV-2

456

therapies. In each case, the therapy was initiated after 2 (â˜…) or 4 (â—) days from

457

symptom onset with 90% inhibition rate. The expected dynamics of the viral loads

458

(top) and the uninfected target cell ratio (bottom) under the hypothetical therapy

459

(antiviral drug or vaccine) for blocking de novo infection, virus production, and

460

promoting cytotoxic effects are shown in (A), (B) and (C), respectively, using the

461

median values of our estimated parameters and an initial viral load that is equal to
21

medRxiv preprint doi: https://doi.org/10.1101/2020.03.23.20040493; this version posted March 27, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
perpetuity.
All rights reserved. No reuse allowed without permission.

462

the detection limit. The coloured solid curves and black dashed curves correspond to

463

SARS-CoV-2 infection dynamics with and without the therapies. In addition, we

464

simulated the model for a range of therapy efficacies and times at which therapies

465

were introduced, and the results are summarised in (D), (E) and (F) for therapies that

466

block de novo infection, block virus production and promote cytotoxic effects,

467

respectively. Darker regions of these panels indicate a larger reduction in AUC of

468

viral load which implies a stronger antiviral effect against SARS-CoV-2 infection. The

469

expected values with t*=0 indicate the antiviral effect of pre-exposure vaccines (or

470

post-exposure prophylactic use of antivirals).

22

Table 1. Estimated parameters for SARS-CoV-2 and MERS-CoV infection obtained from throat swabs
Parameter Name

Symbol (Unit)

SARS-CoV-2

Parameters obtained from fitting to the clinical time-series datasets
Maximum rate constant for viral replication
ğ›¾ğ›¾ (day-1)
Rate constant for virus infection
ğ›½ğ›½ ((copies/ml)-1 day-1)
Death rate of infected cells
ğ›¿ğ›¿ (day-1)
Viral load at symptom onset
ğ‘‰ğ‘‰(0) (copies/ml)
Quantities derived from estimated parameters
Within-hots basic reproduction number
ğ‘…ğ‘…0
Critical inhibition rate
ğ¶ğ¶ âˆ—
Length of virus production
ğ¿ğ¿
Length of viral load above detection limit
ğ‘‡ğ‘‡ğ‘‰ğ‘‰ğ‘‰ğ‘‰ (days)
â€ 

4.55â€ 
6.77 Ã— 10âˆ’5
1.59
21.8
2.87
0.65
0.63
9.34

Median value

23

Mild
3.36
2.10 Ã— 10âˆ’6
2.47
2.43 Ã— 10âˆ’4
1.36
0.26
0.41
10.9

MERS-CoV

Severe
3.76
1.10 Ã— 10âˆ’6
1.32
1.21 Ã— 10âˆ’3
2.84
0.65
0.76
14.0

Table 2. Estimated parameters for SARS-CoV and MERS-CoV infection obtained from nasopharyngeal/sputum/tracheal aspirate
Parameter Name

Symbol (Unit)

SARS-CoV

Parameters obtained from fitting to the clinical time-series datasets
Maximum rate constant for viral replication
ğ›¾ğ›¾ (day-1)
Rate constant for virus infection
ğ›½ğ›½ ((copies/ml)-1 day-1)
Death rate of infected cells
ğ›¿ğ›¿ (day-1)
Viral load at symptom onset
ğ‘‰ğ‘‰(0) (copies/ml)
Quantities derived from estimated parameters
Within-host basic reproduction number
ğ‘…ğ‘…0
Critical inhibition rate
ğ¶ğ¶ âˆ—
Length of virus production
ğ¿ğ¿
Length of viral load above detection limit
ğ‘‡ğ‘‡ğ‘‰ğ‘‰ğ‘‰ğ‘‰ (days)
â€ 

3.09â€ 
8.24 Ã— 10âˆ’3
0.66
2.54
4.67
0.79
1.51
29.6

Median value

24

Mild
3.14
8.37 Ã— 10âˆ’2
0.67
5.89
4.66
0.79
1.49
31.9

MERS-CoV

Severe
3.10
1.31 Ã— 10âˆ’3
0.46
3.05
6.72
0.85
2.17
16.3

20

24

Days after symptom onset

28

Patient S

1010

106
104
102
100

0

4

8

12

16

Days after symptom onset

20

24

Days after symptom onset

28

106
104
102
0

4

8

12

16

100

20

24

Days after symptom onset

28

0

4

8

12

16

20

24

Days after symptom onset

28

Patient P

10

106
104
102
100

0

4

8

12

16

20

24

Days after symptom onset

28

104
102
0

4

8

12

16

20

24

Days after symptom onset

28

Patient Q

10

108
106
104
102
100

0

4

8

12

16

20

24

Days after symptom onset

28

Patient T

106
104
102
0

4

8

12

16

20

24

Days after symptom onset

28

24

28

Patient E

8

10

Ãº

104

Ãº

2

10

100

0

4

8

12

16

20

24

Days after symptom onset

28

Patient I

1010

106
104
102
0

4

8

12

16

20

24

Days after symptom onset

28

Patient M

1010

106
104
102
0

4

8

12

16

8

20

24

Days after symptom onset

28

12

16

20

24

Days after symptom onset

28

Patient F

10

106
104
2

10

100

0

4

8

12

16

20

24

Days after symptom onset

28

Patient J

106
104
102
0

4

8

12

16

20

24

28

20

24

28

Days after symptom onset
Patient N

108
106
104
102
100

0

4

8

12

16

102
100

0

4

8

Days after symptom onset

12

16

20

24

Days after symptom onset

28

Patient G

104
102

10

0

4

8

12

16

20

24

Days after symptom onset

28

ID10

10

106
104
102
0

4

8

12

16

20

24

Days after symptom Onset

28

ID14

106

102
100

â—

â—â— â—â—
0

4

8

12

16

20

24

Days after symptom onset

28

12

16

20

24

28

ID7

104
102
100

0

4

8

12

16

20

24

Days after symptom onset

28

ID11

10

106
104
102
0

4

8

12

16

20

24

Days after symptom onset

28

ID15

106
104
102
0

4

8

12

16

8

20

24

Days after symptom onset

28

12

16

20

24

28

ID8

104
102
100

0

4

8

12

16

20

24

Days after symptom onset

28

ID12

10

106
104
102
0

4

8

12

16

20

24

Days after symptom onset

28

ID16

106
104
102
0

4

8

12

16

0

4

8

12

20

24

Days after symptom onset

28

16

20

24

28

20

24

28

20

24

28

20

24

28

Days after symptom onset
ID9

108
106
104
102
100

0

4

8

12

16

Days after symptom onset
ID13

108
106

â—

104

â—â—

102
100

0

4

8

â—
12

16

Days after symptom onset
ID17

1010

108

100

102

1010

108

100

104

1010

106

1010

108

100

4

Days after symptom onset

108

10

108

100

0

1010

106

1010

108

104

8

108

10

108

100

4

Days after symptom onset

1010

106

100

0

108
106
104
102
100

0

4

8

12

16

10

106
104
2

10

100

0

4

8

12

16

20

24

Days after symptom onset

28

Patient K

106
104
102
0

4

8

12

16

104
102
100

0

4

8

20

24

Days after symptom onset

28

12

16

20

24

Days after symptom onset

28

Patient H

10

106
104
2

10

100

0

4

8

12

16

20

24

Days after symptom onset

28

Patient L

108
106
104
102
100

0

4

8

12

16

ID1

â—â—

108

20

24

Days after symptom onset

28

â—

â—
â—â—

4

10

102
100

0

4

8

12

16

20

24

Days after symptom onset

28

ID5

8

10

â—

104

â— â—

2

10

100

0

4

8

12

16

20

24

28

20

24

28

Days after symptom onset
ID12

1010
8

10

106
104
102
100

0

4

8

12

106
4

10

102
100

0

4

8

16

Days after symptom onset

12

16

20

24

Days after symptom onset

28

ID6

Days after symptom onset

10

106
104
2

10

0

4

8

12

16

106
4

10

102
100

0

4

8

20

24

Days after symptom onset

28

12

16

20

24

Days after symptom onset

28

ID10

10

106
104
2

10

0

4

8

12

16

108
106
10

4

102
100

0

4

8

20

24

Days after symptom onset

28

10

12

16

20

24

28

20

24

28

Days after symptom onset
ID11

1010

8

100

ID4

1010

108

1010

8

100

ID3

1010

108

1010

â—

106

ID2

1010

â— â—

106

1010

8

1010

108

100

106

8

106
104
102
100

0

4

8

12

16

Viral RNA load (copies/ml)

28

Viral RNA load (copies/ml)

24

Viral RNA load (copies/ml)

20

ID6

1010

10

1010

8

1010

108

100

104

1010

8

1010

108

100

4

1010

108

100

0

1010

Ãº

106

102
100

16

108

Viral RNA load (copies/ml)

20

106

8

MERS-CoV

SARS-CoV

Viral RNA load (copies/ml)

16

Days after symptom onset

1010

Viral RNA load (copies/ml)

12

Viral RNA load (copies/ml)

8

104

10

Viral RNA load (copies/ml)

4

106

Patient D

1010

8

Viral RNA load (copies/ml)

0

Viral RNA load (copies/ml)

100

10

Viral RNA load (copies/ml)

102

Patient C

1010

8

Viral RNA load (copies/ml)

Ãº

104

Ãº

Viral RNA load (copies/ml)

Ãº

106

12

106

100

ID5

1010

108

Sputum or Tracheal Aspirate
Patient B

1010

Viral RNA load (copies/ml)

Viral RNA load (copies/ml)

10

Viral RNA load (copies/ml)

Patient A

8

Viral RNA load (copies/ml)

Viral RNA load (copies/ml)

Nasopharyngeal Aspirate
1010

8

1010

108

100

4

Days after symptom onset

1010

106

100

0

Viral RNA load (copies/ml)

Viral RNA load (copies/ml)

28

108

10

108

24

Viral RNA load (copies/ml)

102

10

108

100

104

20

Viral RNA load (copies/ml)

28

Patient O

10

1010

108

24

106

16

Patient L

1010

108

12

Viral RNA load (copies/ml)

16

20

8

102

Viral RNA load (copies/ml)

12

16

4

Days after symptom onset

104

Viral RNA load (copies/ml)

8

12

0

106

100

ID4

1010

108

Viral RNA load (copies/ml)

4

8

28

Viral RNA load (copies/ml)

102

4

24

102

Viral RNA load (copies/ml)

104

0

20

104

Viral RNA load (copies/ml)

106

0

102

10

108

100

104

16

106

100

ID3

1010

108

Viral RNA load (copies/ml)

Patient N

106

12

Patient K

1010

108

100

8

Viral RNA load (copies/ml)

28

4

Days after symptom onset

Viral RNA load (copies/ml)

24

Days after symptom onset

10

Patient I

0

â—

102

Viral RNA load (copies/ml)

20

28

â—

104

100

ID2

1010

â—

106

Viral RNA load (copies/ml)

16

24

Viral RNA load (copies/ml)

12

20

100

108

Viral RNA load (copies/ml)

10

8

16

102

MERS-CoV

102

12

104

Viral RNA load (copies/ml)

104

4

8

106

Viral RNA load (copies/ml)

106

0

4

Days after symptom onset

1010

108

100

0

102

ID1

1010

108

Viral RNA load (copies/ml)

28

104

100

Viral RNA load (copies/ml)

24

106

Viral RNA load (copies/ml)

20

102

Patient F

1010

108

Viral RNA load (copies/ml)

SARS-CoV-2

Viral RNA load (copies/ml)

16

Patient H

1010

Viral RNA load (copies/ml)

12

Viral RNA load (copies/ml)

8

104

Viral RNA load (copies/ml)

4

Days after symptom onset

106

100

Patient E

1010

108

Viral RNA load (copies/ml)

0

Viral RNA load (copies/ml)

102

Viral RNA load (copies/ml)

104

Viral RNA load (copies/ml)

Viral RNA load (copies/ml)

106

100

Patient D

1010

108

Viral RNA load (copies/ml)

Viral RNA load (copies/ml)

Patient C

1010

B

Throat Swab

Throat Swab

Viral RNA load (copies/ml)

A

Days after symptom onset

108

â—
â—

106
104

â—

â—

102
100

â—
0

4

8

12

16

20

24

Days after symptom onset

28

Frequency

0.4
0.3

2

3

4

SARS-CoV
MERS-CoV(severe)
MERS-CoV(mild)

Frequency

0.3

1

0.2

0.2

0.3

0.1

0.0

2.5

5.0

7.5

10.0

SARS-CoV
MERS-CoV(severe)
MERS-CoV(mild)

0.2

0

1

2

1 Î´

3

4

0.0

0.0
0.3

0.00

0.25

0.50

0.75

1.00

0.75

1.00

SARS-CoV
MERS-CoV(severe)
MERS-CoV(mild)

0.2

0.1

0.1
0.0

0.0

0.4
0.3

0.1

0

SARS-CoV-2
MERS-CoV(severe)
MERS-CoV(mild)

Frequency

0.0

0.4

0.2

0.1

0.5

SARS-CoV-2
MERS-CoV(severe)
MERS-CoV(mild)

0.3

0.2

Critical inhibition rate

Frequency

SARS-CoV-2
MERS-CoV(severe)
MERS-CoV(mild)

C

Basic reproduction number
0.5

Frequency

Mean length of virus production
0.5

B

Frequency

A

0.1

0.0

2.5

5.0

R0

7.5

10.0

0.0

0.00

0.25

0.50

1 âˆ’ 1 R0

B

â˜…

106

â—

â—

102

16

100

20

â—

0

4

8

12

16

100

20

Day after symtom onsets

â˜…

1.00

Uninfected cell ratio

Uninfected cell ratio

12

Day after symtom onsets

â˜…

1.00

8

â—

0

4

8

12

16

20

Day after symtom onsets

4

8

12

16

20

Day after symtom onsets

30

40

50

60

70

80

90 100

Antiviral effect of therapy (Îµ)

100

1
1.5

â˜…

2
2.5

80
70
60

3

50

3.5

40

4

â—

4.5

30
20
10

5
10

20

30

40

50

60

70

80

90 100

Antiviral effect of therapy (Îµ)

0

Initiation of therapy (t*)

90

8

12

16

20

0
10

20

30

40

50

60

70

80

10

90 100

Antiviral effect of therapy (Î·)

100

1
1.5
2

â˜…

2.5

80
70
60

3

50

3.5

40

4

â—

4.5

30
20
10

5
10

20

30

40

50

60

70

80

90 100

Antiviral effect of therapy (Î·)

0

20

30

40

50

60

70

80

90 100

Antiviral effect of therapy (Î¸)

100

1

90

Initiation of therapy (t*)

20

4

Day after symtom onsets

F
0

10

20

â—

0

E
0

16

0.25

0

D

12

0.50

0.25

0.25

8

0.75

0.50

0.50

4

Day after symtom onsets

â˜…

1.00

0.75

0.75

0

Uninfected cell ratio

4

â—

104

102

0

Promoting cytotoxicity
â˜…

106

104

102

Initiation of therapy (t*)

â˜…

106

104

100

C

Blocking virus production

Viral RNA load (copies/ml)

Viral RNA load (copies/ml)

Blocking de novo infection

Viral RNA load (copies/ml)

A

90

1.5
2

â˜…

2.5

80
70
60

3

50

3.5

40

4

â—

4.5

30
20
10

5
10

20

30

40

50

60

70

80

90 100

Antiviral effect of therapy (Î¸)

0

Supplementary Appendix

Modelling SARS-CoV-2 Dynamics: Implications for Therapy

Kwang Su Kim1, Keisuke Ejima2, Yusuke Ito1, Shoya Iwanami1, Hirofumi Ohashi3, Yoshiki Koizumi4,
Yusuke Asai4, Shinji Nakaoka5,6, Koichi Watashi3,7,8,9,10, Robin N. Thompson11,12*, and Shingo
Iwami1,9,10,13*

1Department

of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan. 2Department of

Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, IN, USA.
3Department

of Virology II, National Institute of Infectious Diseases, Tokyo, Japan. 4National Center for

Global Health and Medicine, Tokyo, Japan. 5Faculty of Advanced Life Science, Hokkaido University,
Sapporo, Japan. 6PRESTO, JST, Saitama, Japan. 7Department of Applied Biological Science, Tokyo
University of Science, Noda, Japan. 8MIRAI, JST, Saitama, Japan. 9CREST, JST, Saitama, Japan.
10Institute

for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan.

11Christ

Church,

University of Oxford, Oxford OX1 1DP, UK. 12Mathematical Institute, University of Oxford, Oxford OX2
6GG, UK, Fukuoka, UK. 13Science Groove Inc., Fukuoka, Japan.
1

Table S1. Individual estimated parameters and initial values
Patient ID
ğ›¾ğ›¾
ğ›½ğ›½
ğ›¿ğ›¿
ğ‘‰ğ‘‰(0)
ğ¿ğ¿
ğ‘…ğ‘…0
ğ¶ğ¶ âˆ—
SAVS-CoV-2 patients: datasets are obtained from throat swabs
C
4.85 2.08 Ã— 10âˆ’4 1.64
0.61 2.96 0.66
1.66 Ã— 103
âˆ’5
D
4.7
1.52
0.66 3.09 0.68
2.42 Ã— 10
3.71 Ã— 105
âˆ’5
âˆ’5
E
3.65 1.51 Ã— 10
1.7
0.59 2.15 0.53
2.11 Ã— 10
F
4.86 4.15 Ã— 10âˆ’5 1.61
34.9
0.62 3.02 0.67
âˆ’4
3
H
4.7
1.77
0.56 2.66 0.62
5.92 Ã— 10
6.1 Ã— 10
I
4.47 8.08 Ã— 10âˆ’8 1.46
1.18
0.68 3.06 0.67
âˆ’5
K
4.7
1.58
9.1
0.63 2.97 0.66
3.97 Ã— 10
âˆ’6
âˆ’2
L
3.89 6.55 Ã— 10
1.65 0.14 Ã— 10
0.61 2.36 0.58
N
4.7
9.1
0.63 2.97 0.66
3.97 Ã— 10âˆ’5 1.58
âˆ’4
O
4.86 1.09 Ã— 10
1.63
26.7
0.61 2.98 0.66
P
4.7
9.1
0.63 2.97 0.66
3.97 Ã— 10âˆ’5 1.58
âˆ’5
Q
4.63 2.29 Ã— 10
1.60
8.38
0.63 2.89 0.65
S
4.7
9.1
0.63 2.97 0.66
3.97 Ã— 10âˆ’5 1.58
âˆ’5
T
4.49 5.48 Ã— 10
1.57
2.27
0.64 2.86 0.65
MERS-CoV severe patients: datasets are obtained from throat swabs
1
3.57 2.61 Ã— 10âˆ’7 1.16 0.80 Ã— 10âˆ’3 0.86 3.08 0.68
2
3.7
1.00 Ã— 10âˆ’6 1.44 0.99 Ã— 10âˆ’3 0.69 2.57 0.61
3
3.82 2.21 Ã— 10âˆ’6 1.57 2.08 Ã— 10âˆ’3 0.64 2.43 0.59
4
3.00 1.00 Ã— 10âˆ’6 1.48 0.33 Ã— 10âˆ’3 0.68 2.03 0.51
5
3.69 9.96 Ã— 10âˆ’6 1.43 1.03 Ã— 10âˆ’3 0.70 2.58 0.61
6
3.64 1.43 Ã— 10âˆ’6 1.54 1.19 Ã— 10âˆ’3 0.65 2.36 0.58
7
4.09 1.97 Ã— 10âˆ’6 1.19 2.79 Ã— 10âˆ’2 0.84 3.44 0.71
8
3.38 1.34 Ã— 10âˆ’6
2.3
0.47 Ã— 10âˆ’3 0.43 1.47 0.32
âˆ’6
9
4.2
1.58 4.22 Ã— 10âˆ’3 0.63 2.66 0.62
2.04 Ã— 10
MERS-CoV mild patients: datasets are obtained from throat swabs
10
3.35 1.46 Ã— 10âˆ’6 2.63 0.60 Ã— 10âˆ’3 0.38 1.27 0.21
11
3.36 1.46 Ã— 10âˆ’6 2.46 0.58 Ã— 10âˆ’3 0.41 1.37 0.27
12
3.7
2.61 Ã— 10âˆ’6 1.97 0.49 Ã— 10âˆ’3 0.51 1.88 0.47
13
4.19 3.84 Ã— 10âˆ’6 1.98 0.36 Ã— 10âˆ’3 0.51 2.12 0.53
14
3.36 1.46 Ã— 10âˆ’6 2.53 0.63 Ã— 10âˆ’3 0.40 1.33 0.25
15
3.36 1.46 Ã— 10âˆ’6 2.46 0.58 Ã— 10âˆ’3 0.41 1.37 0.27
16
3.52 1.46 Ã— 10âˆ’6 1.76 0.81 Ã— 10âˆ’3 0.57 2.00 0.50
3.47 1.46 Ã— 10âˆ’6 1.89 0.68 Ã— 10âˆ’3 0.53 1.84 0.46
17
SAVS-CoV patients: datasets are obtained from nasopharyngeal aspirate
1.43 4.36 0.77
A
3.05 2.59 Ã— 10âˆ’8 0.70
1.87
âˆ’8
1.43 4.39 0.77
B
3.07 7.67 Ã— 10
0.70
2.28
3.12 2.41 Ã— 10âˆ’7 0.68
3.61
1.47 4.59 0.78
C
âˆ’8
1.92 6.04 0.83
D
3.14 3.31 Ã— 10
0.52
4.55
E
3.05 1.51 Ã— 10âˆ’7 0.86
1.83
1.16 3.55 0.72
F
3.08 1.78 Ã— 10âˆ’7 0.82
2.37
1.22 3.76 0.73
âˆ’8
1.11 3.40 0.71
G
3.06 6.67 Ã— 10
0.90
1.90
1.54 4.69 0.79
H
3.05 3.41 Ã— 10âˆ’8 0.65
1.82
0.99 3.00 0.67
I
3.03 2.82 Ã— 10âˆ’7 1.01
1.45
âˆ’8
1.96 6.12 0.84
J
3.12 1.72 Ã— 10
0.51
3.97
1.59 4.94 0.80
K
3.11 2.62 Ã— 10âˆ’8 0.63
3.23
âˆ’7
1.54 4.78 0.79
L
3.11 1.57 Ã— 10
0.65
3.31
1.59 4.97 0.80
M
3.13 3.22 Ã— 10âˆ’7 0.63
4.32

2

ğ‘‡ğ‘‡ğ‘‰ğ‘‰ğ‘‰ğ‘‰

7.7
10.4
13.2
9.4
6.6
17.4
9.7
13.5
9.7
8.4
9.7
10.4
9.7
9.7
13.7
11.0
9.6
13.2
11.0
10.6
9.9
13.6
9.0
16.3
14.6
9.8
8.1
15.2
14.6
11.0
11.3
23.0
20.6
18.7
26.7
17.6
17.6
18.6
23.4
15.6
28.8
24.2
20.0
18.9

1.82 5.67 0.82 27.6
N
3.12 1.58 Ã— 10âˆ’8 0.55
3.80
MERS-CoV severe patients: datasets are obtained from sputum or tracheal aspirate
2.50 7.75 0.87 39.5
1
3.10 3.26 Ã— 10âˆ’8 0.40
3.14
âˆ’8
2.27 7.09 0.86 30.4
2
3.12 3.79 Ã— 10
0.44
3.75
2.13 6.55 0.85 33.9
3
3.08 0.46 Ã— 10âˆ’8 0.47
2.56
âˆ’8
1.69 5.24 0.81 27.0
4
3.09 1.16 Ã— 10
0.59
2.69
âˆ’8
2.38 7.36 0.86 34.7
5
3.09 1.13 Ã— 10
0.42
2.75
1.89 5.85 0.83 25.4
6
3.10 5.84 Ã— 10âˆ’8 0.53
2.89
MERS-CoV mild patient: datasets are obtained from sputum or tracheal aspirate
1.54 4.86 0.79 18.5
10
3.16 5.84 Ã— 10âˆ’7 0.65
6.19
âˆ’6
1.61 5.05 0.80 14.8
11
3.13 2.60 Ã— 10
0.62
4.85
1.32 4.11 0.76 16.3
12
3.12 4.63 Ã— 10âˆ’7 0.76
3.52

3

